IHE240719C200000
- 0.00
- 0.000.00%
Ishares Trust U.S. Pharmaceuticals Etf Newsroom
RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target
Johnson & Johnson (JNJ) Gets a Buy From RBC Capital
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $167, Maintains Equalweight Rating
Johnson & Johnson Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $169
Stifel Raises Johnson & Johnson's Price Target to $160 From $155
Pfizer's Mixed Outlook: Hold Rating Amidst Vyndaqel's Growth and Falling Demand for Comirnaty and Paxlovid
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Corcept Therapeutics (CORT) and Pfizer (PFE)
TD Cowen Raises Price Target on Eli Lilly to $1,050 From $850
TD Cowen Adjusts Price Target on Merck to $140 From $135
TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $45 From $67
Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained
Goldman Sachs Adjusts Price Target on Merck & Company to $145 From $144
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793
Analysts' Opinions Are Mixed on These Healthcare Stocks: KalVista Pharmaceuticals (KALV), Roche Holding AG (OtherRHHVF) and Pfizer (PFE)
Bristol-Myers Squibb: Hold Rating Maintained Amid Growth Challenges and Uncertain Long-Term Prospects
Eli Lilly and Co Analyst Ratings
Hold Rating on Bristol-Myers Squibb Amid Balanced Strengths and Long-Term Revenue Concerns
Hold Rating Maintained Amid Johnson & Johnson Acquisition and Foreign Exchange Concerns
Eli Lilly & Co (LLY) Gets a Buy From Barclays